The FDA has approved a new clinician application for Medtronic‘s (NYSE:MDT) SynchroMed II intrathecal drug pump. The newly-approved programmer was designed to give doctors visual tools and improved workflows to simplify therapy management.
The medtech titan’s implantable pump, which has been problematic in the past, delivers drugs directly to the fluid around the spinal cord.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves clinician app for Medtronic’s SynchroMed II drug pump appeared first on MassDevice.